Viking Therapeutics Stock (NASDAQ:VKTX)

Forecast Ownership Financials Chart Transcripts

Previous Close

$34.42

52W Range

$18.92 - $81.73

50D Avg

$28.67

200D Avg

$37.24

Market Cap

$3.73B

Avg Vol (3M)

$3.58M

Beta

0.61

Div Yield

VKTX Company Profile

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

Country

Employees

IPO Date

Apr 28, 2015

Website

VKTX Performance

VKTX Financial Summary

	Dec 24	Dec 23	Dec 22
Revenue	-	-	-
Operating Income	$-150.92M	$-100.83M	$-70.36M
Net Income	$-109.96M	$-85.89M	$-67.38M
EBITDA	$-150.92M	$-100.83M	$-70.36M
Basic EPS	$-1.01	$-0.91	$-0.88
Diluted EPS	$-1.01	$-0.91	$-0.88

Fiscal year ends in Dec 24 | Currency in USD

Latest Earnings Call Transcripts

Q2 25Jul 23, 25 | 4:30 PM

Q4 24Feb 05, 25 | 4:30 PM

Q3 24Oct 23, 24 | 4:30 PM

Peer Comparison

Ticker	Company
AXSM	Axsome Therapeutics, Inc.
HEPA	Hepion Pharmaceuticals, Inc.
TERN	Terns Pharmaceuticals, Inc.
VSTM	Verastem, Inc.
TGTX	TG Therapeutics, Inc.
MDGL	Madrigal Pharmaceuticals, Inc.